Agenus Inc. - Special Call Transcript
All right. Hello, everyone. Thank you all for joining. My name is Matt Phipps. I'm a biotech analyst here at William Blair. I do have to first point you all to williamblair.com for a list of disclosures.
But I'm happy today to have both management from Agenus Bio; and Dr. David O'Malley, a professor in the Department of Obstetrics and Gynecology at The Ohio State University, to discuss the really important results presented over the weekend at ESMO combining the PD-1 plus CTLA-4 inhibitor bal/zal combo, at monotherapy and combo in second-line cervical cancer.
So today, we'll kind of review the data, go over some questions both specifically about the data and how this combination could fit into the cervical landscape, also talk about a couple of the other kind of key things being studied in this tumor type and then finish up with more of a kind of corporate look at what's going on.
We do have Dhan Chand here as well, Head of Drug Discovery at Agenus, to chime in for some
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
